NASDAQ:FULC Shareholder Notice: Investigation over Possible Securities Laws Violations by Fulcrum Therapeutics, Inc.

An investigation for investors in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) shares over potential securities laws violations by Fulcrum Therapeutics, Inc. was announced.

Logo

San Diego, CA -- (SBWire) -- 03/14/2023 --Fulcrum Therapeutics, Inc. is under investigation over potential securities laws violations in connection with certain financial statements.

Investors who purchased shares of Fulcrum Therapeutics, Inc. (NASDAQ: FULC), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm focuses on whether a series of statements by Fulcrum Therapeutics, Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Cambridge, MA based Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. On July 17, 2019, Fulcrum Therapeutics, Inc announced the pricing of its initial public offering ("IPO") of 4.5 million shares at $16.00 per share, for gross proceeds of $72.0 million.

On February 24, 2023, Fulcrum Therapeutics, Inc announced that the U.S. Food and Drug Administration (FDA) verbally informed the company that it has issued a full clinical hold regarding the Investigational New Drug application for its sickle-cell disease treatment, FTX-6058, due to previously reported preclinical data.

Shares of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) declined to as low as $4.22 per share on March 10, 2023.

Those who purchased shares of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com

About The Shareholders Foundation
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, , which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in conftact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigation, and/or settlements are not filed/reached and/or related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

Media Relations Contact

Michael Daniels
Shareholders Foundation, Inc.
1-858-779-1554
http://www.ShareholdersFoundation.com

View this press release online at: http://rwire.com/1371992